| Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia SG O'Brien, F Guilhot, RA Larson, I Gathmann, M Baccarani, F Cervantes, ... New England Journal of Medicine 348 (11), 994-1004, 2003 | 4728 | 2003 |
| Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia BJ Druker, F Guilhot, SG O'Brien, I Gathmann, H Kantarjian, N Gattermann, ... New England Journal of Medicine 355 (23), 2408-2417, 2006 | 4466 | 2006 |
| Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients … W Hiddemann, M Kneba, M Dreyling, N Schmitz, E Lengfelder, R Schmits, ... Blood 106 (12), 3725-3732, 2005 | 1745 | 2005 |
| Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study: Presented in part at … CL Sawyers, A Hochhaus, E Feldman, JM Goldman, CB Miller, ... Blood, The Journal of the American Society of Hematology 99 (10), 3530-3539, 2002 | 1535 | 2002 |
| Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study M Talpaz, RT Silver, BJ Druker, JM Goldman, C Gambacorti-Passerini, ... Blood, The Journal of the American Society of Hematology 99 (6), 1928-1937, 2002 | 1479 | 2002 |
| A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoid leukemias OG Ottmann, BJ Druker, CL Sawyers, JM Goldman, J Reiffers, RT Silver, ... Blood, The Journal of the American Society of Hematology 100 (6), 1965-1971, 2002 | 732 | 2002 |
| Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and … T Fischer, RM Stone, DJ DeAngelo, I Galinsky, E Estey, C Lanza, E Fox, ... Journal of clinical oncology 28 (28), 4339-4345, 2010 | 610 | 2010 |
| FLT3 as a therapeutic target in AML: still challenging after all these years T Kindler, DB Lipka, T Fischer Blood, The Journal of the American Society of Hematology 116 (24), 5089-5102, 2010 | 483 | 2010 |
| Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger … O Hermine, E Hoster, J Walewski, A Bosly, S Stilgenbauer, C Thieblemont, ... The Lancet 388 (10044), 565-575, 2016 | 470 | 2016 |
| Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial H Serve, U Krug, R Wagner, MC Sauerland, A Heinecke, U Brunnberg, ... Journal of Clinical Oncology 31 (25), 3110-3118, 2013 | 391 | 2013 |
| A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies F Giles, T Fischer, J Cortes, G Garcia-Manero, J Beck, F Ravandi, ... Clinical Cancer Research 12 (15), 4628-4635, 2006 | 379 | 2006 |
| Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome S Kayser, RF Schlenk, MC Londono, F Breitenbuecher, K Wittke, J Du, ... Blood, The Journal of the American Society of Hematology 114 (12), 2386-2392, 2009 | 352 | 2009 |
| Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia RM Stone, T Fischer, R Paquette, G Schiller, CA Schiffer, G Ehninger, ... Leukemia 26 (9), 2061-2068, 2012 | 349 | 2012 |
| AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations C Choudhary, J Schwäble, C Brandts, L Tickenbrock, B Sargin, ... Blood 106 (1), 265-273, 2005 | 340 | 2005 |
| Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain F Heidel, FK Solem, F Breitenbuecher, DB Lipka, S Kasper, MH Thiede, ... Blood 107 (1), 293-300, 2006 | 324 | 2006 |
| Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of … A Hochhaus, B Druker, C Sawyers, F Guilhot, CA Schiffer, J Cortes, ... Blood, The Journal of the American Society of Hematology 111 (3), 1039-1043, 2008 | 287 | 2008 |
| Very-late-antigen-4 (VLA-4)-mediated brain invasion by neutrophils leads to interactions with microglia, increased ischemic injury and impaired behavior in experimental stroke J Neumann, M Riek-Burchardt, J Herz, TR Doeppner, R König, H Hütten, ... Acta neuropathologica 129, 259-277, 2015 | 260 | 2015 |
| Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia R Hehlmann, U Berger, M Pfirrmann, H Heimpel, A Hochhaus, J Hasford, ... Blood, The Journal of the American Society of Hematology 109 (11), 4686-4692, 2007 | 227 | 2007 |
| Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia SG O'Brien, P Meinhardt, E Bond, J Beck, B Peng, C Dutreix, G Mehring, ... British journal of cancer 89 (10), 1855-1859, 2003 | 198 | 2003 |
| Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma A Josting, H Müller, P Borchmann, JW Baars, B Metzner, H Döhner, ... Journal of clinical oncology 28 (34), 5074-5080, 2010 | 196 | 2010 |
